Skip to main content

Epitomics Signs Contract to Develop Antibodies for NCI's Proteomics Initiative

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Antibody firm Epitomics today announced it has signed a contract with SAIC-Frederick to develop rabbit monoclonal antibodies in support of the National Cancer Institute's proteomics initiative.

SAIC-Frederick operates under a contract with NCI's Clinical Proteomic Technologies for Cancer program.

Under the terms of Epitomics' contract, the Burlingame, Calif.-based company will develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers. The peptides will then be used to quantify biomarkers by mass spectrometry-based technologies, such as stable isotope standards and capture by anti-peptide antibodies (SISCAPA) and immuno-matrix-assisted laser desorption/ionization (iMALDI), Epitomics said in a statement.

The firm has completed the first phase of the project to generate and affinity-purify rabbit polyclonal antibodies against the biomarkers. It will now move into the second phase to develop rabbit monoclonal antibodies against selected biomarkers that have been validated.

CPTC is a five-year, $104 million effort to develop new proteomics tools and technologies to accelerate discovery and clinical research. One part of the initiative is to develop better antibodies and reagents for the proteomics community.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.